{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Syncopation Life Sciences Inc., (\"Syncopation\"), located in Palo Alto, California.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/03/01/2022-04245.html","cfr_references":[],"citation":"87 FR 11451","comment_url":null,"comments_close_on":"2022-03-16","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 16, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2022-04245","effective_on":null,"end_page":11452,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/03/01/2022-04245.xml","html_url":"https://www.federalregister.gov/documents/2022/03/01/2022-04245/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-chimeric","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-04245?publication_date=2022-03-01","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-03-01/2022-04245/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":328,"last_updated":"2026-07-26 06:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-03-01/pdf/2022-04245.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-04245.pdf?1646055931","publication_date":"2022-03-01","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/03/01/2022-04245.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:25:46Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":11451,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies","toc_doc":"Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies That Are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.:\n","topics":[],"type":"Notice","volume":87}